Krystle Lang Kuhs
Last active: 3/20/2020


I am a cancer prevention researcher and molecular epidemiologist.  My research focus is the prevention of infection-associated cancers.  My program focuses on developing novel molecular predictors of head and neck cancer risk, response to treatment and risk of recurrence, with a particular focus on head and neck cancers caused by infections such as human papillomavirus. Thus, the goals of my research program are to improve outcomes for head and neck cancer patients by using molecular markers: a) for the early detection of head and neck cancers; b) to improve the precision treatment of head and neck cancers by refining pre-treatment risk stratification and; c) for the early detection of recurrences.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer. Lang Kuhs KA, Wood CB, Wiggleton J, Aulino JM, Latimer B, Smith DK, Bender N, Rohde S, Mannion K, Kim Y, Sinard R, Langerman A, Fleischer A, Fakhry C, Waterboer T, Netterville JL (2020) Cancer 126(11): 2658-2665
    › Primary publication · 32129894 (PubMed) · PMC7829679 (PubMed Central)
  2. Early onset oral tongue squamous cell carcinoma: Associated factors and patient outcomes. Campbell BR, Sanders CB, Netterville JL, Sinard RJ, Rohde SL, Langerman A, Mannion K, Kim YJ, Murphy BA, Lewis JS, Warner JL, Smith DK, Lang Kuhs KA (2019) Head Neck 41(6): 1952-1960
    › Primary publication · 30633435 (PubMed) · PMC7010313 (PubMed Central)
  3. Early onset oral tongue cancer in the United States: A literature review. Campbell BR, Netterville JL, Sinard RJ, Mannion K, Rohde SL, Langerman A, Kim YJ, Lewis JS, Lang Kuhs KA (2018) Oral Oncol : 1-7
    › Primary publication · 30527223 (PubMed) · PMC7039330 (PubMed Central)
  4. Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. Mirghani H, Lang Kuhs KA, Waterboer T (2018) Oral Oncol : 108-114
    › Primary publication · 29909884 (PubMed)
  5. T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. Lang Kuhs KA, Lin SW, Hua X, Schiffman M, Burk RD, Rodriguez AC, Herrero R, Abnet CC, Freedman ND, Pinto LA, Hamm D, Robins H, Hildesheim A, Shi J, Safaeian M (2018) PLoS One 13(1): e0178167
    › Primary publication · 29385144 (PubMed) · PMC5791954 (PubMed Central)
  6. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL (2017) Cancer 123(22): 4382-4390
    › Primary publication · 28950407 (PubMed) · PMC5743332 (PubMed Central)
  7. Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. Van Dyke AL, Lang Kuhs KA, Shiels MS, Koshiol J, Trabert B, Loftfield E, Purdue MP, Wentzensen N, Pfeiffer RM, Katki HA, Hildesheim A, Kemp TJ, Pinto LA, Chaturvedi AK, Safaeian M (2017) PLoS One 12(7): e0182359
    › Primary publication · 28753646 (PubMed) · PMC5533447 (PubMed Central)
  8. The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. Beachler DC, Lang Kuhs KA, Struijk L, Schussler J, Herrero R, Porras C, Hildesheim A, Cortes B, Sampson J, Quint W, Gonzalez P, Kreimer AR (2017) Sex Transm Dis 44(7): 442-449
    › Primary publication · 28608796 (PubMed) · PMC6299456 (PubMed Central)
  9. Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, Williams C, Freedman ND, Huang WY, Purdue MP, Michel A, Pawlita M, Brennan P, Waterboer T (2017) J Natl Cancer Inst 109(8)
    › Primary publication · 28376197 (PubMed) · PMC5967352 (PubMed Central)
  10. HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. Beachler DC, Waterboer T, Pierce Campbell ChM, Ingles DJ, Kuhs KA, Nyitray AG, Hildesheim A, Pawlita M, Kreimer AR, Giuliano AR (2016) Papillomavirus Res : 141-144
    › Primary publication · 28239675 (PubMed) · PMC5322843 (PubMed Central)
  11. Hepatitis C Virus NS3/NS4A DNA Vaccine Induces Multiepitope T Cell Responses in Rhesus Macaques Mimicking Human Immune Responses. Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB (2012) Mol Ther 20(3): 669-678
    › Primary publication · 28160634 (PubMed)
  12. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T (2016) Cancer Epidemiol : 46-52
    › Primary publication · 27010729 (PubMed) · PMC4910878 (PubMed Central)
  13. Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity. Finnberg NK, Gokare P, Navaraj A, Lang Kuhs KA, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS (2016) Cancer Res 76(3): 700-12
    › Primary publication · 26609054 (PubMed) · PMC5001853 (PubMed Central)
  14. Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR, Peters MG, Plankey M, Sharp GB, Strickler HD, Villacres MC, Quinn TC, Gange SJ, Prokunina-Olsson L, Greenblatt RM, O'Brien TR (2015) PLoS One 10(10): e0138827
    › Primary publication · 26431156 (PubMed) · PMC4592222 (PubMed Central)
  15. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L (2015) J Hepatol 63(5): 1103-10
    › Primary publication · 26186989 (PubMed) · PMC4615534 (PubMed Central)
  16. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. O'Brien TR, Lang Kuhs KA, Pfeiffer RM (2014) Open Forum Infect Dis 1(3): ofu110
    › Primary publication · 25734178 (PubMed) · PMC4324232 (PubMed Central)
  17. Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Lang Kuhs KA, Hildesheim A, Trabert B, Kemp TJ, Purdue MP, Wentzensen N, Katki HA, Pinto LA, Loftfield E, Safaeian M, Chaturvedi AK, Shiels MS (2015) Cancer Epidemiol Biomarkers Prev 24(5): 825-32
    › Primary publication · 25713025 (PubMed) · PMC4417370 (PubMed Central)
  18. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. Kreimer AR, Brennan P, Lang Kuhs KA, Waterboer T, Clifford G, Franceschi S, Michel A, Willhauck-Fleckenstein M, Riboli E, Castellsagué X, Hildesheim A, Fortner RT, Kaaks R, Palli D, Ljuslinder I, Panico S, Clavel-Chapelon F, Boutron-Ruault MC, Mesrine S, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Cross AJ, Bueno-de-Mesquita HB, Vineis P, Larrañaga N, Pala V, Sánchez MJ, Navarro C, Barricarte A, Tumino R, Khaw KT, Wareham N, Boeing H, Steffen A, Travis RC, Quirós JR, Weiderpass E, Pawlita M, Johansson M (2015) J Clin Oncol 33(8): 877-84
    › Primary publication · 25667279 (PubMed) · PMC4348636 (PubMed Central)
  19. Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. Lang Kuhs KA, Anantharaman D, Waterboer T, Johansson M, Brennan P, Michel A, Willhauck-Fleckenstein M, Purdue MP, Holcátová I, Ahrens W, Lagiou P, Polesel J, Simonato L, Merletti F, Healy CM, Kjaerheim K, Conway DI, Macfarlane TV, Thomson P, Castellsagué X, Znaor A, Black A, Huang WY, Krogh V, Trichopoulou A, Bueno-de-Mesquita HB, Clavel-Chapelon F, Weiderpass E, Ekström J, Riboli E, Tjønneland A, Sánchez MJ, Travis RC, Hildesheim A, Pawlita M, Kreimer AR (2015) Cancer Epidemiol Biomarkers Prev 24(4): 683-9
    › Primary publication · 25623733 (PubMed) · PMC4383678 (PubMed Central)
  20. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M, Costa Rica Vaccine Trial Group (2014) Am J Epidemiol 180(6): 599-607
    › Primary publication · 25139208 (PubMed) · PMC4157699 (PubMed Central)
  21. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR, Costa Rica Vaccine Trial Group (2014) J Infect Dis 210(12): 1890-9
    › Primary publication · 24958910 (PubMed) · PMC4271025 (PubMed Central)
  22. Induction of intrahepatic HCV NS4B, NS5A and NS5B-specific cellular immune responses following peripheral immunization. Lang Kuhs KA, Toporovski R, Yan J, Ginsberg AA, Shedlock DJ, Weiner DB (2012) PLoS One 7(12): e52165
    › Primary publication · 23284919 (PubMed) · PMC3528776 (PubMed Central)
  23. Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver. Lang Kuhs KA, Toporovski R, Ginsberg AA, Olsen AL, Shedlock DJ, Morrow MP, Yan J, Wells RG, Weiner DB (2011) Hum Vaccin 7(12): 1326-35
    › Primary publication · 22108033 (PubMed) · PMC3338931 (PubMed Central)
  24. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB (2012) Mol Ther 20(3): 669-78
    › Primary publication · 21952169 (PubMed) · PMC3293616 (PubMed Central)
  25. Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin. Kang DW, Kim YS, Lim KS, Kim MS, Pearce LV, Pavlyukovets VA, Tao AK, Lang-Kuhs KA, Blumberg PM, Lee J (2010) Bioorg Med Chem 18(22): 8092-105
    › Primary publication · 20937561 (PubMed) · PMC3420354 (PubMed Central)
  26. Immunotherapy for HCV infection: next steps. Lang K, Weiner DB (2008) Expert Rev Vaccines 7(7): 915-23
    › Primary publication · 18767942 (PubMed)
  27. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB (2008) Vaccine 26(49): 6225-31
    › Primary publication · 18692108 (PubMed) · PMC4477808 (PubMed Central)